Please login to the form below

Not currently logged in

thyroid cancer

This page shows the latest thyroid cancer news and features for those working in and with pharma, biotech and healthcare.

Merck KGaA to make $3m payout to patients after drug formulation complaints

Merck KGaA to make $3m payout to patients after drug formulation complaints

According to lawyers working on behalf of the plaintiffs, the replacement caused patients to experience severe side effects, including hair loss, memory loss, weight gain and in some cases, thyroid cancer. ... Despite the company’s claims, French group

Latest news

More from news
Approximately 9 fully matching, plus 53 partially matching documents found.

Latest Intelligence

  • Deal Watch March 2016 Deal Watch March 2016

    Ipsen paid $200m upfront for the rights (ex-North America &Japan) to commercialise Cometriq for medullary thyroid cancer and other indications. ... Collaboration – discovery, development &commercialisation. $965. Exelixis/ Ipsen. Cabozantinib (Renal

  • EATRIS and the new age of partnering EATRIS and the new age of partnering

    In a display of its global ambition, EATRIS is joining with Cancer Research UK to bring representatives of the US's National Cancer Institute to a workshop in Brussels in October ... The first one we initiated in this matchmaking process was a bio-marker

  • Interview: AstraZeneca's Susan Galbraith Interview: AstraZeneca's Susan Galbraith

    As ASCO commences the company's VP of oncology talks to PMLiVE about its pipeline prospects in cancer. ... The company is building on its recent oncology launches of Caprelsa (vandetanib) for medullary thyroid cancer - approved in Europe in 2012 - and

  • Pharma deals during August 2013 Pharma deals during August 2013

    In 2012 these drugs generated $289.6m in revenue for Onyx. Included in the Onyx clinical pipeline are sorafenib (in phase III for thyroid cancer) also partnered with Bayer and carfilzomib, ... This protracted process is indicative of the now “holy

  • Eisai: Bucking the trend with R&D growth Eisai: Bucking the trend with R&D growth

    III, this time for thyroid cancer. ... The company is also still very much in launch mode with its first cancer drug Halaven, which has been brought to most of the major European markets.

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Subscribe to our email news alerts

Featured jobs


Add my company
Six Degrees Medical Consulting

For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...

Latest intelligence

Five big changes in the healthcare comms landscape
The world of healthcare has changed very greatly in the five years since The Difference Collective launched. Our agile model and talented team have enabled us to keep pace with...
Early communications in Pharma: How effective pre-approval comms delivers launch success
What communications are required for a successful launch...
Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....